NCT06660992View on ClinicalTrials.gov

A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis

PHASE3RecruitingINTERVENTIONAL
Enrollment

669

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

November 28, 2026

Study Completion Date

January 27, 2027

Conditions
Non-cystic Fibrosis Bronchiectasis
Interventions
DRUG

HSK31858, tablet

HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 52-week treatment period in patients with non-cystic fibrosis bronchiectasis

DRUG

Placebo

the placebo comparator of study

Trial Locations (2)

Unknown

RECRUITING

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

RECRUITING

Yixing People's Hospital, Yixingcun

All Listed Sponsors
lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY